Obsessive-Compulsive Disorder Treatment Guidelines

First-Line Treatment

The American College of Psychiatrists recommends fluoxetine 40-80 mg daily or sertraline 150-200 mg daily as the first-line pharmacological treatment for OCD due to their superior safety profiles, FDA approval, and equivalent efficacy to other SSRIs 1
All SSRIs show similar effect sizes for OCD treatment, so selection should be based on safety profile, drug interactions, and FDA approval status 1
Higher doses than those used for depression are required for optimal OCD efficacy, with fluoxetine 60-80 mg daily and paroxetine 60 mg daily being recommended 2
Allow 8-12 weeks at maximum tolerated dose before declaring treatment failure, though early response by 2-4 weeks predicts eventual treatment success 1
Maintain treatment for a minimum of 12-24 months after achieving remission due to high relapse risk after discontinuation 1, 3

Clomipramine 150-250 mg daily should be reserved for patients who fail at least one adequate SSRI trial, defined as 8-12 weeks at maximum tolerated dose 1, 3
SSRIs are preferred over clomipramine as first-line agents due to superior safety and tolerability profiles, which is critical for the long-term treatment adherence required in OCD 1, 3

Approximately 50% of patients fail to fully respond to first-line SSRI monotherapy, with even higher rates in real-world settings 3
CBT augmentation of SSRIs shows larger effect sizes than antipsychotic augmentation and should be the preferred first augmentation strategy when available 1, 3, 4
Risperidone or aripiprazole have the strongest evidence for SSRI-resistant OCD, with approximately one-third of patients showing clinically meaningful response 3, 4
N-acetylcysteine has the strongest evidence among glutamatergic agents, with three out of five randomized controlled trials showing superiority to placebo 3

Do not declare SSRI failure before 8-12 weeks at maximum tolerated dose, as premature switching is a common error 1
Do not use depression-level SSRI doses for OCD, as this is inadequate and will lead to treatment failure 1, 2
Do not discontinue effective treatment prematurely, and maintain for a minimum of 12-24 months after remission to prevent relapse 1, 3
Do not ignore pharmacogenetic risk factors, and screen for CYP2D6 poor metabolizer status before high-dose fluoxetine or paroxetine, especially with cardiac risk factors 2